Scienza e Tecnologia
Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020
Total Returns from the Novo Holdings Investment Portfolio amounted to DKK 23.9 billion (€3.2 billion), while dividends and income from participating in the share repurchase programmes of the Novo Group companies (Novo Nordisk and Novozymes) totalled DKK 13.5 billion (€1.8 billion).
Kasim Kutay , CEO of Novo Holdings, said: "2021 was a very satisfactory year for Novo Holdings. Besides strong returns from the Novo Group companies, our Investment Portfolio delivered strong results across all segments. We are very pleased to be executing on our key objective of generating attractive returns for the Novo Nordisk Foundation, which the Foundation can distribute for purposes that improve the lives of people and the sustainability of the planet."
The Novo Holdings Investment Portfolio comprises Life Science Investments ( Novo Seeds , Novo Growth, Novo Ventures and Novo Principal Investments), making up 52% of the portfolio, and Novo Capital Investors (48% of the portfolio). The Life Science Investment Portfolio and Novo Capital Investors contributed evenly with returns of close to DKK 12 billion (€1.6 billion) each.
By year-end, the total Novo Holdings portfolio counted 151 companies, including Novo Nordisk and Novozymes.
"2021 was a year of very high activity across all our verticals, and we have increased our investments both geographically and sector-wise. Our Principal Investments team in
Boston acquired two companies, and our team in
Singapore invested in a number of highly promising healthcare companies across
Southeast Asia . On top of that, the Novo Ventures team executed 46 investments and eight IPOs, while
Novo Seeds continues to be a key player in building a sustainable Nordic life science ecosystem,"
Kasim Kutay said.
"Further, we have successfully increased our presence in the bioindustrials sector, which is a very important strategic area to Novo Holdings, while Novo Capital Investors further increased our investments into real assets,"
Kasim Kutay added.
At the end of 2021, the Life Science Investment Portfolio generated a 10-year average return of 17%, while the Novo Capital Investors Portfolio generated a 10-year average return of 10%. The total Novo Holdings Investment Portfolio 10-year average return stands at 14%.
Read the
Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.
Novo Holdings is recognised as a leading international life science investor with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: www.novoholdings.dk
The Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives established in Denmark in 1924. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. The Foundation's mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society. Further information: https://novonordiskfonden.dk/en/